Publications

Title

Author

Year

Online mis/disinformation and vaccine hesitancy in the era of COVID-19: Why we need an eHealth literacy revolution.

Dib, F; MAYAUD, P; Chauvin, P; Launay, O;

2021

Human vaccines & immunotherapeutics, (2021).18 1 10.1080/21645515.2021.1874218.

Country Level COVID-19 Vaccination Prioritisation Decision Support Tool for WHO EUR.

LIU, Y; Sandmann, F; BARNARD, RC; PEARSON, CA B; LSHTM CMMID COVID-19 Working Group,; DAVIES, NG; JIT, M;

2021

, ShinyApps.io (2021).

An interactive website tracking COVID-19 vaccine development.

Shrotri, M; SWINNEN, T; KAMPMANN, B; PARKER, EP K;

2021

LANCET GLOBAL HEALTH, (2021).9 5 10.1016/S2214-109X(21)00043-7.

Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics.

NKURUNUNGI, G; ZIRIMENYA, L; NATUKUNDA, A; Nassuuna, J; Oduru, G; Ninsiima, C; Zziwa, C; Akello, F; Kizindo, R; Akello, M; KALEEBU, P; WAJJA, A; Luzze, H; COSE, S; WEBB, E; ELLIOTT, AM; POPVAC trial team,;

2021

BMJ open, (2021).11 2 10.1136/bmjopen-2020-040425.

Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation differences in VACcine responses' (POPVAC) programme.

NKURUNUNGI, G; ZIRIMENYA, L; Nassuuna, J; NATUKUNDA, A; Kabuubi, PN; Niwagaba, E; Oduru, G; Kabami, G; Amongin, R; Mutebe, A; Namutebi, M; Zziwa, C; Amongi, S; Ninsiima, C; Onen, C; Akello, F; Sewankambo, M; Kiwanuka, S; Kizindo, R; Kaweesa, J; COSE, S; WEBB, E; ELLIOTT, AM; POPVAC trial team,; POPVAC trial team principal investigator,;

2021

BMJ open, (2021).11 2 10.1136/bmjopen-2020-040426.

Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (P...

NATUKUNDA, A; NKURUNUNGI, G; ZIRIMENYA, L; Nassuuna, J; Oduru, G; Amongin, R; Kabuubi, PN; Mutebe, A; Onen, C; Amongi, S; Nakazibwe, E; Akello, F; Kiwanuka, S; Kiwudhu, F; Sewankambo, M; Nsubuga, D; Kizindo, R; STAEDKE, SG; COSE, S; WEBB, E; ELLIOTT, AM; POPVAC trial team,;

2021

BMJ open, (2021).11 2 10.1136/bmjopen-2020-040427.

Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme.

ZIRIMENYA, L; NKURUNUNGI, G; Nassuuna, J; NATUKUNDA, A; Mutebe, A; Oduru, G; Kabami, G; Akurut, H; Onen, C; Namutebi, M; Serubanja, J; Nakazibwe, E; Akello, F; Tumusiime, J; Sewankambo, M; Kiwanuka, S; Kiwudhu, F; Kizindo, R; Kizza, M; WAJJA, A; COSE, S; Muwanga, M; WEBB, E; ELLIOTT, AM; POPVAC trial team,;

2021

BMJ open, (2021).11 2 10.1136/bmjopen-2020-040430.

Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled tri...

Leach, AJ; MULHOLLAND, EK; Santosham, M; Torzillo, PJ; McIntyre, P; Smith-Vaughan, H; Wilson, N; Arrowsmith, B; Beissbarth, J; Chatfield, MD; Oguoma, VM; Licciardi, P; Skull, S; Andrews, R; Carapetis, J; McDonnell, J; Krause, V; Morris, PS;

2021

Vaccine: X, (2021).7, 10.1016/j.jvacx.2021.100086.

Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?.

DOCKRELL, HM; BUTKEVICIUTE, E;

2021

Vaccine, (2021).40 11 10.1016/j.vaccine.2021.01.068.

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.

Wouters, OJ; Shadlen, KC; Salcher-Konrad, M; Pollard, AJ; LARSON, HJ; Teerawattananon, Y; JIT, M;

2021

Lancet (London, England), (2021).397 10278 10.1016/S0140-6736(21)00306-8.